Metabolic · Body Composition · Cardiovascular
Liraglutide
Also known as: Victoza, Saxenda, NN2211
A daily-injected GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda), preceding the longer-acting semaglutide in clinical use.
Sign in to add to watchlistEvidence strength
Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.
Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.
Key Takeaways
- ›Liraglutide is a once-daily GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Victoza) and weight management (Saxenda).
- ›It was the first GLP-1 drug shown to reduce cardiovascular events and the first approved for weight management.
- ›Newer weekly agents (semaglutide, tirzepatide) generally produce larger weight and glucose effects.
- ›Gastrointestinal side effects are most common; weight tends to return after stopping.
- ›It is a prescription medicine. Work with a licensed healthcare professional on any treatment decision.
What It Is
Liraglutide is a synthetic GLP-1 analog engineered with a single amino acid substitution and a fatty acid acylation that binds albumin and extends the plasma half-life to approximately 13 hours, supporting once-daily subcutaneous administration. It was the second GLP-1 receptor agonist approved for type 2 diabetes (after exenatide) and the first to receive a chronic-weight-management indication, in 2014.
Novo Nordisk developed liraglutide as part of its broader GLP-1 program, with subsequent successors including semaglutide. Mechanistically, GLP-1 receptor activation enhances glucose-dependent insulin secretion, slows gastric emptying, reduces glucagon secretion in hyperglycemic conditions, and reduces appetite through central pathways. The shorter half-life relative to semaglutide and tirzepatide requires daily rather than weekly administration but produces a more rapid washout if discontinued.
Unlock the full Liraglutide research report
Vial+ opens the mechanism breakdown, evidence graphs, potential benefits, safety considerations, regulatory status, a plain-language explainer, and 4 cited sources.
Get Vial+ — $20 one-timeLifetime access · the community forum stays free.
Disclaimer: This content is for educational and research purposes only and is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.